Europe — EMA
Ocrevus (Ocrelizumab)
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a strength/form for intravenous infusion use. It is indicated for the treatment of multiple sclerosis in adult patients.
Request sourcing
What is Ocrelizumab?
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a strength/form for intravenous infusion use. It is indicated for the treatment of multiple sclerosis in adult patients. GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Ocrelizumab used for?
Ocrevus is a disease‑modifying therapy that targets the multiple sclerosis pathway.
- Relapsing‑remitting multiple sclerosis (RRMS): Reduces the frequency of clinical relapses and slows disability progression. - Primary progressive multiple sclerosis (PPMS): Delays worsening of neurological function. - Adult patients with multiple sclerosis: Provides a long‑term treatment option to modify disease activity.
What are the side effects of Ocrelizumab?
Adverse reactions to Ocrevus vary in frequency and severity.
Common Side Effects: - Infusion‑related reactions (fever, chills, rash). - Upper respiratory tract infection. - Headache. - Fatigue. - Nausea.
Serious or Rare Side Effects: - Severe infections, including opportunistic infections. - Hepatitis B reactivation. - Progressive multifocal leukoencephalopathy (PMF P). - Malignancies. - Hypersensitivity anaphylaxis. - Cardiac arrest .
What precautions apply to Ocrelizumab?
Ocrevus … … … …
